Patents by Inventor Du An Yan

Du An Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6825164
    Abstract: The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid &bgr; peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: November 30, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan, Berislav Zlokovic
  • Patent number: 6677299
    Abstract: The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid &bgr; peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: January 13, 2004
    Assignee: The Trustee of Columbia University in the city of New York
    Inventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan, Berislav Zlokovic
  • Patent number: 6563015
    Abstract: The invention provides for a non-human transgenic animal whose cells contain a recombinant DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which encodes human receptor for advanced glycation endproducts (RAGE), and (b) a nerve tissue specific promoter operatively linked to a DNA sequence encoding a mutant human amyloid precursor protein hAPP695, hAPP751 and hAPP770 bearing mutations linked to familial Alzheimer's disease in humans, wherein said non-human transgenic animal exhibits at least one phenotype from the group consisting of: increased expression of M-CSF gene in cerebral cortex; increased expression of IL-6 gene in cerebral cortex; increased neuronal stress; increased neurotoxicity; neuron loss; increased level of activated form of caspase 3 in brain; and increased level of phosphorylated tau protein in brain.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: May 13, 2003
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan
  • Patent number: 6555651
    Abstract: The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: April 29, 2003
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David Stern, Shi Du Yan, Ann Marie Schmidt, Ira Lamster
  • Publication number: 20030037344
    Abstract: This invention provides a method for evaluating the ability of a compound to inhibit neurotoxicity which comprises (a) contacting a cell which expresses a receptor for advanced glycation end product protein and a mutant presenilin-2 protein in a cell culture and the compound; (b) determining the level of cell death in the cell culture; and (c) comparing the level of cell death determined in step (b) with the amount determined in the absence of the compound so as to evaluate the ability of the compound to inhibit neurotoxicity.
    Type: Application
    Filed: December 23, 1997
    Publication date: February 20, 2003
    Inventors: DAVID STERN, SHI DU YAN, BENJAMIN WOLOZIN
  • Publication number: 20020122799
    Abstract: The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.
    Type: Application
    Filed: June 1, 2001
    Publication date: September 5, 2002
    Inventors: David M. Stern, Kevan Herold, Shi Du Yan, Ann Marie Schmidt, Ira Lamster
  • Publication number: 20020116725
    Abstract: The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid &bgr; peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.
    Type: Application
    Filed: November 5, 2001
    Publication date: August 22, 2002
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan, Berislav Zlokovic
  • Publication number: 20010053357
    Abstract: The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Seq. I.D. No. 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE.
    Type: Application
    Filed: October 9, 1997
    Publication date: December 20, 2001
    Inventors: DAVID STERN, SHI DU YAN, ANN MARIE SCHMIDT, IRA LAMSTER
  • Patent number: 6268479
    Abstract: The present invention provides an isolated nucleic acid encoding an endoplasmic reticulum associated amyloid-beta peptide binding (ERAB) polypeptide. The ERAB polypeptide may comprise human ERAB polypeptide. The present invention provides a purified ERAB polypeptide, as well as a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent in amount effective to inhibit ERAB polypeptide binding to amyloid-beta peptide so as to thereby treat the neurodegenerative condition.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: July 31, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Shi Du Yan